Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis A Randomized Clinical Trial

• 資料種別: 博士論文
• タイトル: Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis A Randomized Clinical Trial
• 著者・編者: Oki, Ryosuke; Izumi, Yuishin; Fujita, Koji; Miyamoto, Ryosuke; Nodera, Hiroyuki; Sato, Yasutaka; Sakaguchi, Satoshi; Nokihara, Hiroshi; Kanai, Kazuaki; Tsunemi, Taiji; Hattori, Nobutaka; Hatanaka, Yuki; Sonoo, Masahiro; Atsuta, Naoki; Sobue, Gen; Shimizu, Toshio; Shibuya, Kazumoto; Ikeda, Ken; Kano, Osamu; Nishinaka, Kazuto; Kojima, Yasuhiro; Oda, Masaya; Komai, Kiyonobu; Kikuchi, Hitoshi; Kohara, Nobuo; Urushitani, Makoto; Nakayama, Yoshiaki; Ito, Hidefumi; Nagai, Makiko; Nishiyama, Kazutoshi; Kuzume, Daisuke; Shimohama, Shun; Shimohata, Takayoshi; Abe, Koji; Ishihara, Tomohiko; Onodera, Osamu; Isose, Sagiri; Araki, Nobuyuki; Morita, Mitsuya; Noda, Kazuyuki; Toda, Tatsushi; Maruyama, Hirofumi; Furuya, Hirokazu; Teramukai, Satoshi; Kagimura, Tatsuo; Noma, Kensuke; Yanagawa, Hiroaki; Kuwabara, Satoshi; Kaji, Ryuji
• 著者標目: Oki, Ryosuke; Izumi, Yuishin; Fujita, Koji; Miyamoto, Ryosuke; Nodera, Hiroyuki; Sato, Yasutaka; Sakaguchi, Satoshi; Nokihara, Hiroshi; Kanai, Kazuaki; Tsunemi, Taiji; Hattori, Nobutaka; Hatanaka, Yuki; Sonoo, Masahiro; Atsuta, Naoki; Sobue, Gen; Shimizu, Toshio; Shibuya, Kazumoto; Ikeda, Ken; Kano, Osamu; Nishinaka, Kazuto; Kojima, Yasuhiro; Oda, Masaya; Komai, Kiyonobu; Kikuchi, Hitoshi; Kohara, Nobuo; Urushitani, Makoto; Nakayama, Yoshiaki; Ito, Hidefumi; Nagai, Makiko; Nishiyama, Kazutoshi; Kuzume, Daisuke; Shimohama, Shun; Shimohata, Takayoshi; Abe, Koji; Ishihara, Tomohiko; Onodera, Osamu; Isose, Sagiri; Araki, Nobuyuki; Morita, Mitsuya; Noda, Kazuyuki; Toda, Tatsushi; Maruyama, Hirofumi; Furuya, Hirokazu; Teramukai, Satoshi; Kagimura, Tatsuo; Noma, Kensuke; Yanagawa, Hiroaki; Kuwabara, Satoshi; Kaji, Ryuji
• 出版事項: American Medical Association
• 出版年月日等: 2022-05-09
• 出版年（W3CDTF）: 2022-05-09
• 並列タイトル等: 発症早期ALS患者に対する超高用量メチルコバラミンの有効性・安全性について : ランダム化比較試験
• タイトル（掲載誌）: JAMA Neurology
• 巻号年月日等（掲載誌）: 79 6
• 掲載巻: 79
• 掲載号: 6
• 掲載ページ: 575-583
• ISSN（掲載誌）: ISSN : 2168-6149; ISSN : 2168-6157
• 授与機関名: 徳島大学
• 授与年月日: 2023-04-27
• 報告番号: 甲第3738号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Amyotrophic Lateral Sclerosis (ALS); Ultrahigh-Dose Methylcobalamin; Treatment; Updated Awaji criteria; Homocysteine
• 対象利用者: 一般
• 一般注記: Importance: Post hoc analysis in a phase 2/3 trial indicated ultra-high dose methylcobalamin slowed decline of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score at week 16 as well as at week 182, without increase of adverse events, in patients with amyotrophic lateral sclerosis (ALS) who were enrolled within 1 year from onset. Objective: To validate the efficacy and safety of ultra-high dose methylcobalamin for patients with ALS enrolled within 1 year of onset. Design: A multicenter, placebo-controlled, double-blind, randomized phase 3 trial with 12-week observation and 16-week randomized period, conducted from October 2017 to September 2019. Setting: Twenty-five neurology centers in Japan. Participants: Patients with ALS diagnosed within 1 year of onset by the updated Awaji criteria were initially enrolled. Of those, patients fulfilling the following criteria after 12-week observation were eligible for randomization: 1- or 2-point decrease in ALSFRS-R total score, a percent forced vital capacity over 60%, no history of noninvasive respiratory support and tracheostomy, and being ambulant. The target number was 64 in both methylcobalamin and placebo groups. Of 203 patients enrolled in the observation, 130 patients (age, 61.0 ± 11.7 years; female, 56) met the criteria and were randomly assigned through an electronic web-response system to methylcobalamin or placebo (65 for each). Of these, 129 patients were eligible for the full analysis set, and 126 completed the double-blind stage. Interventions: Intramuscular injection of methylcobalamin 50 mg or placebo twice weekly for 16 weeks. Main outcomes and measures: The primary endpoint was change in ALSFRS-R total score from baseline to week 16 in the full analysis set. Results: The least-squares mean difference in ALSFRS-R total score at week 16 of the randomized period was 1.97 points greater with methylcobalamin than placebo (−2.66 versus −4.63; 95% CI, 0.44–3.50; P = 0.012). The incidence of adverse events was similar between the two groups. Conclusions and relevance: Ultra-high dose methylcobalamin was efficacious in slowing functional decline and safe in the 16-week treatment period in ALS patients in the early stage and with moderate progression rate. Trial registration: UMIN-CTR Identifier: UMIN000029588 (umin.ac.jp/ctr); ClinicalTrials.gov Identifier: NCT03548311 (clinicaltrials.gov)
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1001/jamaneurol.2022.0901
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/118371/20230630131707802277/k3738_abstract.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/118371/20230630131707887844/k3738_review.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/118371/20230721114311436477/k3738_fulltext.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/118371/20230721114311552670/Supplementary File.pdf fulltext